Skip to content
The County has given the green light to AltMed to establish a cultivation

SARASOTA, Florida (April 26, 2018) – Alternative Medical Enterprises, LLC (“AltMed”), a fully integrated company that brings pharmaceutical industry precision to the development, production and dispensing of medical cannabis, today announced it has closed a private placement financing of $35.4 million with an affiliate of MainLine Investment Partners, LLC (“MLIP”) and other investors.

“This Financing will help us to conduct a robust launch in the massive medical marijuana marketplace of Florida and build out our 25 authorized dispensaries,” said Matthew Duffy, AltMed President and COO. “It will also enable us to accelerate the expansion of our cultivation capabilities and increase our footprint in Arizona. We anticipate significant growth over the next few years as we expand our licensed facilities to meet the needs of medical cannabis patients in Florida and Arizona.”

Additionally, the investment will provide capital to grow AltMed’s award winning MÜV brand of premium cannabis products nationally & internationally. Funding will also clear the balance sheet of debt and allow AltMed’s industry leading R&D to continue to prosper.

MLIP is a sophisticated institutional investor focusing on investments in operating businesses and real estate assets, as well as private wealth management and multifamily residential property management. MLIP has approximately $1 billion of invested capital and assets under management. Its principals have managed over $3 billion of equity capital commitments in alternative investments since 1987.

“We see our investment in AltMed as a rare opportunity to gain a strong foothold in a once in a generation new growth industry,” said William Landman, managing principal of MainLine Investment Partners. “AltMed has demonstrated that they are and will be industry leaders in Florida, Arizona, nationally and globally.”

“The fact that MainLine has chosen AltMed for one of its first strategic investments in the cannabis industry serves as a powerful validation for our results to date, and our potential for future growth,” said Duffy.

AltMed’s award winning MÜV premium cannabis products are sold in dispensaries across Arizona and are expected to be available for Florida patients beginning this summer. AltMed Florida is currently in the process of expanding its state-of-the-art cultivation facility from 50,000 to 150,000 square feet to accommodate anticipated demand.

About MÜV™

The MÜV™ brand of medical cannabis infused products launched in Arizona in 2016 and quickly gained international attention and recognition. MÜV Dispensaries by AltMed Florida was formed a year later through the partnership of AltMed Enterprises and Plants of Ruskin, a multi-generational Florida agricultural leader. Through continual research and development, MÜV has received multiple patents for its award-winning MÜV Products line that provides quality, consistent and reliable medical cannabis products to patients at all 29 locations (one in Arizona, 28 in Florida, and more added each month). Patients are encouraged to place reservations online at for in-store pickup, order for delivery, or visit any one of the 27 MÜV Dispensaries for alternative medical cannabis medicine you can trust.

About Plants Of Ruskin, LLC – D.B.A. AltMed Florida, LLC

With a focus on quality and attention to detail, Plants of Ruskin has more than 35 years of experience in providing seedlings to farmers for vegetable and medical product production. Plants of Ruskin founders, the Dickman Family, are 4th generation farmers with a long history of working in conjunction with the University of Florida, including an endowed chair specifically dedicated to plant improvement.

About AltMed Enterprises

Alternative Medical Enterprises, LLC, headquartered in Sarasota, FL and doing business as AltMed Enterprises, is a fully integrated medical cannabis company that brings compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids.

Forward-Looking Statements – To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.